首页> 外文期刊>Life sciences >Dipeptidyl peptidase IV (DPPIV) enzyme activity on immature T-cell line R1.1 is down-regulated by dynorphin-A(1-17) as a non-substrate inhibitor.
【24h】

Dipeptidyl peptidase IV (DPPIV) enzyme activity on immature T-cell line R1.1 is down-regulated by dynorphin-A(1-17) as a non-substrate inhibitor.

机译:未成熟的T细胞系R1.1上的二肽基肽酶IV(DPPIV)酶活性被作为非底物抑制剂的强啡肽-A(1-17)下调。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

In this study we examined surface expression of CD26 and the corresponding enzyme activity of dipeptidyl peptidase IV (DPPIV) on the cells of immature murine T-cell line, R1.1. The data obtained have shown that R1.1 cells express high density of surface CD26 as compared to normal thymus cells. This was associated with strong enzyme activity, which, based on substrates and inhibitor specificity, corresponded to DPPIV. The DPPIV enzyme activity of R1.1 cells was 10 times stronger than that found on normal murine thymus cells (V(max) = 39 micromol/min/10(6) cells, vs 3.7 micromol/min/10(6) cells, respectively). Upon activation with anti-CD3, up-regulation of both membrane CD26, as well as of DPPIV enzyme activity on R1.1 cells were observed. The finding of strong DPPIV on R1.1 cells makes them suitable model for testing putative substrates/inhibitors of the enzyme in its natural microenvironment. Since in addition to strong DPPIV, R1.1 cells also express kappa opioid receptors (KOR) [European Journal of Pharmacology 227 (1992) 257], we tested the effect of dynorphin-A(1-17), an endogenous opioid peptide with KOR selectivity, on DPPIV of R1.1 cells. Dynorphin-A(1-17) down-regulated DPPIV in a dose-dependent manner, with the potency similar to that of substance P, a known natural DPPIV substrate [Journal of Pharmacology and Experimental Therapeutics 260 (1992) 1257]. DPPIV down-regulation was resistant to bestatin and thiorphan, the inhibitors of two cell surface peptidases (APN and NEP, respectively) with potential of dynorphin-A(1-17) degradation, suggesting that the mechanism underlying the observed effect does not involve degradative products of dynorphin-A(1-17). DPPIV down-regulation was also resistent to KOR antagonist, NBI, suggesting that the mechanism underlying the observed phenomenon involves neither cointernalization of KOR and DPPIV. Collectively, cells of immature T cell line, R1.1 exert strong DPPIV enzyme activity, which could be down-regulated in the presence of dynorphin-A(1-17) by mechanismthat presumably includes non-substrate inhibition. By down-regulating DPPIV, dynorphin-A(1-17) may indirectly affect activity and/or specificity of natural substrates of DPPIV, such as substance P, RANTES, and endomorphins.
机译:在这项研究中,我们检查了CD26的表面表达以及二肽基肽酶IV(DPPIV)在未成熟鼠T细胞系R1.1细胞上的相应酶活性。所获得的数据表明,与正常胸腺细胞相比,R1.1细胞表达高密度的表面CD26。这与强大的酶活性有关,基于底物和抑制剂的特异性,其对应于DPPIV。 R1.1细胞的DPPIV酶活性比正常鼠胸腺细胞(V(max)= 39 micromol / min / 10(6)细胞,而3.7 micromol / min / 10(6)细胞强10倍,分别)。在用抗CD3激活后,观察到膜CD26以及R1.1细胞上DPPIV酶活性的上调。在R1.1细胞上发现强DPPIV,使其成为测试其天然微环境中假定的酶底物/抑制剂的合适模型。由于除强DPPIV外,R1.1细胞还表达κ阿片受体(KOR)[欧洲药理学杂志227(1992)257],我们测试了强啡肽-A(1-17)的内源性阿片肽与对R1.1细胞的DPPIV的KOR选择性。强啡肽-A(1-17)以剂量依赖性方式下调DPPIV,其效力类似于物质P(已知的天然DPPIV底物)的效力[药理学和实验治疗学杂志260(1992)1257]。 DPPIV下调对Bestatin和thiorphan这两种细胞表面肽酶(分别为APN和NEP)的抑制剂具有强啡肽A(1-17)降解的潜力具有抵抗力,表明观察到的作用的潜在机制不涉及降解强啡肽-A(1-17)的产品。 DPPIV下调也抵抗KOR拮抗剂NBI,这表明观察到的现象的潜在机制既不涉及KOR和DPPIV的共价化。总的来说,未成熟的T细胞系R1.1的细胞具有很强的DPPIV酶活性,在强啡肽-A(1-17)存在的情况下,可能通过非底物抑制机制下调了DPPIV酶的活性。通过下调DPPIV,强啡肽-A(1-17)可能间接影响DPPIV天然底物(例如P物质,RANTES和内啡肽)的活性和/或特异性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号